Table 5.

Diagnostic test performance calculated from 2 × 2 tables for presence of homozygous deficient genotype.

Study	Year	Calculated sensitivity	Calculated specificity	Calculated PPV	Calculated NPV	Ref.
TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c
Ben Salah	2013	100.0%	100.0%	100.0%	100.0%	[13]
Fangbin	2012	†	100.0%	†	100.0%	[26]
Ganiere-Monteil	2004	100.0%	100.0%	100.0%	100.0%	[58]
Gazouli	2012	33.3%	98.9%	85.7%	88.1%	[29]
Serpe	2009	100.0%	100.0%	100.0%	100.0%	[35]
von Ahsen	2005	†	100.0%	†	100.0%	[65]
Winter	2007	0.0%	100.0%	†	99.2%	[10]
Xin	2009	†	100.0%	†	100.0%	[36]
Zhang	2007	†	100.0%	†	100.0%	[37]
TPMT*2, TPMT*3a, TPMT*3c
Fakhoury	2007	100.0%	100.0%	100.0%	100.0%	[25]
Ford	2009	†	†	†	†	[28]
Hindorf	2012	86.0%	100.0%	100.0%	99.9%	[30]
Liang	2013	†	100.0%	†	100.0%	[14]
Ma	2006	†	100.0%	†	100.0%	[39]
Marinaki	2003	†	100.0%	†	100.0%	[60]
TPMT*2, TPMT*3b, TPMT*3c
Larussa	2012	16.7%	97.8%	50.0%	89.8%	[31]
Milek	2006	†	100.0%	†	100.0%	[33]
Wusk	2004	†	.	†	†	[11]
TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c, TPMT*3d
Schaeffeler	2004	100.0%	100.0%	100.0%	100.0%	[62]
Schwab	2002	100.0%	100.0%	100.0%	100.0%	[64]
Wennerstrand	2013	†	100.0%	†	100.0%	[16]
TPMT*3a, TPMT*3b, TPMT*3c
Langley	2002	0.0%	100.0%	†	98.1%	[59]
Lennard	2013	†	†	†	100.0%	[32]
TPMT*2, TPMT*3
Ford	2006	100.0%	100.0%	100.0%	100.0%	[27]
TPMT*1, TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c
Jorquera	2012	†	100.0%	†	100.0%	[38]
TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c, TPMT*6
Loennechen	2001	†	100.0%	†	100.0%	[23]
TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c, TPMT*3d, TPMT*8
Oselin	2006	†	†	†	†	[34]
TPMT*1, TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c, TPMT*1S, TPMT*1A, TPMT*7, TPMT *3d
Spire-Vayron de la Moureyre	1998	100.0%	100.0%	100.0%	100.0%	[67]
TPMT*2, TPMT*3a, TPMT*3b, TPMT*3c, TPMT*3D, TPMT*4, TPMT*5, TPMT*6, TPMT*7
Spire-Vayron de la Moureyre	1998	100.0%	100.0%	100.0%	100.0%	[24]
TPMT*1, TPMT*2, TPMT*3a, TPMT*3c
Yates	1997	100.0%	100.0%	100.0%	100.0%	[66]

^†Unable to calculate.

NPV: Negative predictive value; PPV: Positive predictive value.